Inactive Instrument

Pear Therapeutics, Inc.

PEAR

US7047231052

Biotechnology & Medical Research

Pear Therapeutics, Inc. Announces Resignation of Corey Mccann, M.D., Ph.D. as Chief Executive Officer

April 07, 2023 at 09:02 pm IST

Pear Therapeutics, Inc. announced resignation of Corey McCann, M.D., Ph.D. as the Chief Executive Officer.

Latest news about Pear Therapeutics, Inc.

Pear Therapeutics, Inc. Went Out of Business	23/05	CI
Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc.	08/05	CI
Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	22/03	CI
Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	04/03	CI
Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	12/02	CI
Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	13/12	CI
First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	04/23/04	CI
First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	20/23/20	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23/23/23	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23/23/23	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	21/23/21	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	20/23/20	CI
Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	19/23/19	CI
Bidding Procedure Approved for Pear Therapeutics, Inc.	28/23/28	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from S&P TMI Index	21/23/21	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from NASDAQ Composite Index	18/23/18	CI
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected	14/23/14	MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports	14/23/14	MT
Top Premarket Decliners	14/23/14	MT
Motion for Joint Administration Approved for Pear Therapeutics, Inc.	12/23/12	CI
Top Midday Decliners	10/23/10	MT
Pear Therapeutics Intends to Pursue a Sale of the Business or Assets	08/23/08	CI
Pear Therapeutics, Inc. Announces Executive Changes	07/23/07	CI
Pear Therapeutics, Inc. Announces Resignation of Corey Mccann, M.D., Ph.D. as Chief Executive Officer	07/23/07	CI
Motion for Joint Administration Filed by Pear Therapeutics, Inc.	07/23/07	CI

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+34.14%	5.11TCr
IQVIA HOLDINGS INC.	-6.54%	3.94TCr
LONZA GROUP AG	+34.92%	3.85TCr
ICON PUBLIC LIMITED COMPANY	+12.62%	2.64TCr
CELLTRION, INC.	-12.11%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	2.1TCr
UNITED THERAPEUTICS CORPORATION	+43.73%	1.4TCr
MEDPACE HOLDINGS, INC.	+31.81%	1.25TCr
BIO-TECHNE CORPORATION	-4.54%	1.16TCr

Other Biotechnology & Medical Research